Clinical Trial Update: Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating Rituximab plus Zanubrutinib versus Rituximab alone in untreated Splenic marginal zone lymphoma, with the study currently active bu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Splenic Marginal Zone Lymphoma

Drugs mentioned

• Rituximab (rituximab)
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: International Extranodal Lymphoma Study Group (IELSG) | Conditions: Splenic Marginal Zone Lymphoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING